Guided Therapeutics Enters into Preliminary Research Agreement with Konica Minolta Opto in Anticipation of Asian Distribution; Plan to Initiate Screening Trials for LuViva Advanced Cervical Scan
NORCROSS, Ga.–(BUSINESS WIRE)– Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP), developer of a rapid and painless biophotonic testing platform for the early detection of cancer, today announced that it has entered into a preliminary agreement with Konica Minolta Opto, Inc. of Tokyo, to conduct clinical and market research for the LuViva™ Advanced Cervical Scan product in certain Asian markets. As part of the agreement, the two companies also plan to conduct a clinical trial to establish screening claims for LuViva, as a method to replace the Pap test for early cervical disease detection in international markets. […]
Guided Therapeutics, Inc. (OTCBB: GTHP) is developing a rapid and painless test for the early detection of disease that leads to cervical cancer. The technology is designed to quickly eliminate false positive Pap and HPV results and discover cervical disease missed by existing tests. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are known immediately.